Mano Manoharan
Senior Vice President, Innovation Chemistry Alnylam Pharmaceuticals
Mano Manoharan, PhD, is the Senior Vice President of Innovation Chemistry and an Alnylam Distinguished Scientist at Alnylam Pharmaceuticals. A pioneering leader in the field of RNAi therapeutics, he has been instrumental in the discovery and development of novel RNAi medicines for over two decades. Prior to his tenure at Alnylam, Dr. Manoharan spent 13 years in leadership roles at Ionis Pharmaceuticals. He completed his post-doctoral studies in bioorganic chemistry at Yale University and holds a PhD from the University of North Carolina at Chapel Hill. He is a frequent invited speaker on medicinal chemistry and oligonucleotide therapeutics.
Seminars
- Leveraging advanced chemical modifications to develop novel conjugate platforms, to enable delivery beyond the liver with high specificity, to expand treatable diseases to include neurological disorders and rare cancers
- Applying bespoke chemical modifications to peptide-based and other conjugate systems to improve endosomal escape and intracellular siRNA bioavailability to boost gene silencing efficacy while reducing dose frequency and toxicity
- Implementing a next-generation, data-rich platform for the rapid design and optimization of novel ligand-siRNA chemistries to accelerate optimization of delivery chemistries for unmet clinical needs, for future-proofing Alnylam’s pipeline against GalNAc’s limitations
The future of RNAi lies at the intersection of precision medicine, AI-driven innovation, and strategic combination approaches. This panel explores how integrating cutting-edge technologies like AI target discovery with synergistic modalities can unlock new therapeutic potential. Experts will discuss multi-target silencing strategies, new target molecule classes, and how to future-proof RNAi pipelines to lead the next wave of transformative treatments. Join us to gain actionable insights on positioning your RNAi therapeutics at the forefront of precision medicine by discussing:
- Exploring AI-driven target discovery and combination therapies with CAR-T or radiotherapy to accelerate identification of disease-specific genes with high clinical relevance to enable faster precision RNAi therapy development
- Predicting future combination therapy strategies to stay ahead of emerging trends in multi-target silencing, for the expansion of treatment options for complex diseases
- Strategizing how to position pipelines at the forefront of next-gen RNAi innovation
